To include your compound in the COVID-19 Resource Center, submit it here.

Efficacy data for risdiplam could position Roche’s oral SMA therapy ahead of Spinraza

Even with a PDUFA delay for Roche’s SMA therapy earlier this month, efficacy data from the Phase II/III FIREFISH trial of risdiplam released Tuesday cast a favorable light on the oral therapy when compared

Read the full 346 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE